An understanding of the role of immunomodulation in reducing UV induced immunosuppression and in preventing photocarcinogenesis would add to our knowledge of host resistance factors against carcinogenesis and could aid in terms of prevention of malignancy. UVB induced immunosuppression is critical for the development of UVB induced skin tumors, and it is important to know if prevention of this immunosuppression results in host resistance to photocarcinogenesis. The mouse skin model of UVB tumorigenesis will be used in these studies because the kinetics of UV dosage, immunosuppression, and tumor formation have been delineated in this system. C3H/HeN mice will be treated for three weeks with selected doses of the immunomodulators: vitamin E, selenium, diethyldithiocarbamate, or recombinant interleukin-2. Combinations of the most chemopreventive agents at nontoxic doses will be investigated later in the study. After three weeks of exposure to immunomodulators, the mice will be UVB radiated dorsally to induce immunosuppression. Resistance of the treated mice to UV induced tumors will be assessed by measuring primary tumor growth and by measuring outgrowth of implanted antigenic, syngeneic UV induced tumor cells (UV22). The modulation of in vivo rejection will be studied by quantification of leukocyte subpopulations infiltrating into the UV22 tumor challenges. Unirradiated mice reject these tumors, whereas irradiated mice do not. Comparisons of leukocyte phenotypes in challenges of the same tumor (UV22), undergoing rejection versus acceptance should reveal which immunological cells are important for rejection. Immunosuppression will be assessed by the capacity of splenocytes from treated or untreated, UV irradiated mice to transfer suppression to naive mice. The ability of UVB irradiation to systemically effect the tumoricidal capacity of peritoneal macrophages, and the influence of immunomodulators on this effect, will be measured. These experiments should clarify whether prevention of immunosuppression will effectively prevent photocarcinogenesis.
| Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A et al. (2018) Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene 37:5633-5647 |
| Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278 |
| Knights-Mitchell, Shellie S; Romanowski, Marek (2018) Near-Infrared Activated Release of Doxorubicin from Plasmon Resonant Liposomes. Nanotheranostics 2:295-305 |
| Chen, Yin; Vasquez, Monica M; Zhu, Lingxiang et al. (2017) Effects of Retinoids on Augmentation of Club Cell Secretory Protein. Am J Respir Crit Care Med 196:928-931 |
| Yamamoto, Hiroyuki; Ryu, Joohyun; Min, Eli et al. (2017) TRAF1 Is Critical for DMBA/Solar UVR-Induced Skin Carcinogenesis. J Invest Dermatol 137:1322-1332 |
| Zykova, Tatyana A; Zhu, Feng; Wang, Lei et al. (2017) The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis. EBioMedicine 18:73-82 |
| Einspahr, Janine G; Curiel-Lewandrowski, Clara; Calvert, Valerie S et al. (2017) Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light. NPJ Precis Oncol 1: |
| Gao, Ge; Zhang, Tianshun; Wang, Qiushi et al. (2017) ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK. Mol Cancer Ther 16:1843-1854 |
| Glazer, Evan S; Bartels, Peter H; Lian, Fangru et al. (2016) Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases. Melanoma Res 26:261-6 |
| Franklin, Stephen J; Younis, Usir S; Myrdal, Paul B (2016) Estimating the Aqueous Solubility of Pharmaceutical Hydrates. J Pharm Sci 105:1914-1919 |
Showing the most recent 10 out of 395 publications
